|Articles|May 8, 2007
ISTA Pharmaceuticals releases preliminary results from phase II/III study of bepotastine
ISTA Pharmaceuticals Inc. announced results from the preliminary analysis of its phase II/III clinical study of bepotastine for the treatment of allergic conjunctivitis. The study evaluated two concentrations of bepotastine, each dosed once daily and twice daily.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
























